Simultaneous Deletion of Virulence Factors and Insertion of Antigens into the Infectious Laryngotracheitis Virus Using NHEJ-CRISPR/Cas9 and Cre-Lox System for Construction of a Stable Vaccine Vector.
Cre–lox
ILTV
genome editing
recombinant vaccines
vaccine
virus control
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
05 Dec 2019
05 Dec 2019
Historique:
received:
14
11
2019
revised:
01
12
2019
accepted:
02
12
2019
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
11
12
2019
Statut:
epublish
Résumé
Infectious laryngotracheitis virus (ILTV) is a promising vaccine vector due to its heterologous gene accommodation capabilities, low pathogenicity, and potential to induce cellular and humoral arms of immunity. Owing to these characteristics, different gene-deletion versions of ILTVs have been successfully deployed as a vector platform for the development of recombinant vaccines against multiple avian viruses using conventional recombination methods, which are tedious, time-demanding, and error-prone. Here, we applied a versatile, and customisable clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 accompanied with Cre-Lox system to simultaneously delete virulence factors and to insert foreign genes in the ILTV genome. Using this pipeline, we successfully deleted thymidine kinase (
Identifiants
pubmed: 31817447
pii: vaccines7040207
doi: 10.3390/vaccines7040207
pmc: PMC6963826
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M008681/1 and BBS/E/I/00001852
Pays : United Kingdom
Organisme : British Council
ID : 172710323 and 332228521
Références
Virus Res. 2016 Oct 2;225:33-39
pubmed: 27619840
J Virol. 1998 Jan;72(1):847-52
pubmed: 9420298
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Vet Microbiol. 1995 Sep;46(1-3):221-31
pubmed: 8545960
Microbiol Immunol. 2014 Sep;58(9):513-22
pubmed: 25040500
Virus Res. 2005 Sep;112(1-2):108-14
pubmed: 16022905
Vaccine. 2009 Aug 13;27(37):5085-90
pubmed: 19573638
J Gen Virol. 2007 Mar;88(Pt 3):732-42
pubmed: 17325345
Cell Res. 2014 Jan;24(1):122-5
pubmed: 24296780
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Biotechnol Lett. 2015 Jun;37(6):1265-72
pubmed: 25724716
J Gen Virol. 1983 Sep;64 (Pt 9):2069-72
pubmed: 6193248
J Gen Virol. 1992 Sep;73 ( Pt 9):2415-20
pubmed: 1328497
Avian Dis. 1990 Jul-Sep;34(3):646-56
pubmed: 2173534
J Virol. 2015 May;89(9):5176-9
pubmed: 25741005
J Virol. 2016 Jul 11;90(15):6989-6998
pubmed: 27226370
Virology. 1989 Aug;171(2):623-5
pubmed: 2548334
Virology. 1995 Jun 1;209(2):304-14
pubmed: 7778265
J Gen Virol. 2003 Jun;84(Pt 6):1415-25
pubmed: 12771409
Virus Res. 1993 Aug;29(2):125-40
pubmed: 8212855
Arch Virol. 2009;154(1):171-7
pubmed: 19066710
J Gen Virol. 2007 Mar;88(Pt 3):719-31
pubmed: 17325344
Vet Microbiol. 1995 Jun;45(1):71-80
pubmed: 7653030
Vaccine. 2018 Dec 18;36(52):7975-7986
pubmed: 30448332
Sci Rep. 2016 Jan 18;6:19176
pubmed: 26777545
Vaccine. 1998 May;16(8):802-9
pubmed: 9627937
EMBO J. 2003 Feb 17;22(4):833-46
pubmed: 12574120
Virus Res. 2016 Sep 2;223:197-205
pubmed: 27507009
J Virol. 2000 Nov;74(22):10401-6
pubmed: 11044084
Nat Rev Mol Cell Biol. 2014 Jan;15(1):7-18
pubmed: 24326623
Sci Rep. 2017 May 3;7(1):1478
pubmed: 28469192
Arch Virol. 2006 Jul;151(7):1281-9
pubmed: 16502283
Avian Dis. 1991 Apr-Jun;35(2):348-55
pubmed: 1649591
J Gen Virol. 2006 Oct;87(Pt 10):2839-47
pubmed: 16963741
PLoS One. 2013 Jun 28;8(6):e67598
pubmed: 23840745
Cell. 2014 Jun 5;157(6):1262-78
pubmed: 24906146
PLoS Pathog. 2014 May 01;10(5):e1004090
pubmed: 24788700
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Avian Dis. 2003 Apr-Jun;47(2):330-42
pubmed: 12887192
Vet Res. 2007 Mar-Apr;38(2):261-79
pubmed: 17296156
Vaccine. 2009 Jan 29;27(5):773-85
pubmed: 19041677
Virus Genes. 1996;12(2):107-16
pubmed: 8879127